Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Anticancer drugs: Assault on MALT1.

Burgess DJ.

Nat Rev Drug Discov. 2013 Feb;12(2):100. doi: 10.1038/nrd3942. No abstract available.

PMID:
23370242
2.

The proteolytic activity of the paracaspase MALT1 is key in T cell activation.

Rebeaud F, Hailfinger S, Posevitz-Fejfar A, Tapernoux M, Moser R, Rueda D, Gaide O, Guzzardi M, Iancu EM, Rufer N, Fasel N, Thome M.

Nat Immunol. 2008 Mar;9(3):272-81. doi: 10.1038/ni1568. Epub 2008 Feb 10.

PMID:
18264101
3.

Therapeutics: Assault on MALT1.

Burgess DJ.

Nat Rev Cancer. 2013 Feb;13(2):80. doi: 10.1038/nrc3451. Epub 2013 Jan 10. No abstract available.

PMID:
23303135
4.
5.

Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase.

Hailfinger S, Lenz G, Thome M.

Curr Opin Chem Biol. 2014 Dec;23:47-55. doi: 10.1016/j.cbpa.2014.09.025. Epub 2014 Oct 4. Review.

PMID:
25285878
6.

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.

Hailfinger S, Lenz G, Ngo V, Posvitz-Fejfar A, Rebeaud F, Guzzardi M, Penas EM, Dierlamm J, Chan WC, Staudt LM, Thome M.

Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19946-51. doi: 10.1073/pnas.0907511106. Epub 2009 Nov 6. Erratum in: Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2677.

7.

Changes in the MALT1-A20-NF-κB expression pattern may be related to T cell dysfunction in AML.

Shi L, Chen S, Lu Y, Wang X, Xu L, Zhang F, Yang L, Wu X, Li B, Li Y.

Cancer Cell Int. 2013 Apr 30;13(1):37. doi: 10.1186/1475-2867-13-37.

8.

B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G.

Blood. 2017 Jan 19;129(3):333-346. doi: 10.1182/blood-2016-05-718775. Epub 2016 Nov 18.

PMID:
27864294
9.

Detection of recombinant and cellular MALT1 paracaspase activity.

Nagel D, Krappmann D.

Methods Mol Biol. 2015;1280:239-46. doi: 10.1007/978-1-4939-2422-6_13.

PMID:
25736752
10.

Probes to monitor activity of the paracaspase MALT1.

Hachmann J, Edgington-Mitchell LE, Poreba M, Sanman LE, Drag M, Bogyo M, Salvesen GS.

Chem Biol. 2015 Jan 22;22(1):139-47. doi: 10.1016/j.chembiol.2014.11.011. Epub 2014 Dec 31.

11.

Differential requirement for Malt1 in T and B cell antigen receptor signaling.

Ruland J, Duncan GS, Wakeham A, Mak TW.

Immunity. 2003 Nov;19(5):749-58.

12.

The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.

Pelzer C, Cabalzar K, Wolf A, Gonzalez M, Lenz G, Thome M.

Nat Immunol. 2013 Apr;14(4):337-45. doi: 10.1038/ni.2540. Epub 2013 Feb 17.

PMID:
23416615
13.

Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?

Demeyer A, Staal J, Beyaert R.

Trends Mol Med. 2016 Feb;22(2):135-50. doi: 10.1016/j.molmed.2015.12.004. Epub 2016 Jan 17. Review.

PMID:
26787500
14.

MALT1 protease: a new therapeutic target in B lymphoma and beyond?

McAllister-Lucas LM, Baens M, Lucas PC.

Clin Cancer Res. 2011 Nov 1;17(21):6623-31. doi: 10.1158/1078-0432.CCR-11-0467. Epub 2011 Aug 25. Review.

15.

Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.

Fontán L, Melnick A.

Clin Cancer Res. 2013 Dec 15;19(24):6662-8. doi: 10.1158/1078-0432.CCR-12-3869. Epub 2013 Sep 4. Review.

16.

Detection and measurement of paracaspase MALT1 activity.

Hailfinger S, Pelzer C, Thome M.

Methods Mol Biol. 2014;1133:177-88. doi: 10.1007/978-1-4939-0357-3_11.

PMID:
24567102
17.
18.

Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets.

Tusche MW, Ward LA, Vu F, McCarthy D, Quintela-Fandino M, Ruland J, Gommerman JL, Mak TW.

J Exp Med. 2009 Nov 23;206(12):2671-83. doi: 10.1084/jem.20091802. Epub 2009 Nov 16.

19.

MALT1 Protease Activity Controls the Expression of Inflammatory Genes in Keratinocytes upon Zymosan Stimulation.

Schmitt A, Grondona P, Maier T, Brändle M, Schönfeld C, Jäger G, Kosnopfel C, Eberle FC, Schittek B, Schulze-Osthoff K, Yazdi AS, Hailfinger S.

J Invest Dermatol. 2016 Apr;136(4):788-97. doi: 10.1016/j.jid.2015.12.027. Epub 2016 Jan 6.

20.

MALT1 Inhibition of Oral Carcinoma Cell Invasion and ERK/MAPK Activation.

Chiba T, Soeno Y, Shirako Y, Sudo H, Yagishita H, Taya Y, Kawashiri S, Okada Y, Imai K.

J Dent Res. 2016 Apr;95(4):446-52. doi: 10.1177/0022034515621740. Epub 2015 Dec 23.

PMID:
26701346

Supplemental Content

Support Center